Monoclonal antibodies shown effective for breakthrough COVID-19 casesNew research from the Mayo Clinic shows monoclonal antibodies reduce the risk of hospitalization 77% in 1,395 patient who had breakthrough COVID-19 infections.
The research was published yesterday in the Journal of Infectious Diseases.To conduct the retrospective study, researchers compared outcomes of confirmed COVID-19 patients who were fully vaccinated treated with either bamlanivimab, bamlanivimab-etesevimab, or casirivimab-imdevimab, as single infusion from January to August 16, 2021, to those who did not receive treatment.The average age of a breakthrough patients was 54 years.